After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Gilead Sciences (GILD) stock in focus as cancer drug Trodelvy outperforms chemotherapy in a Phase 3 trial for advanced triple ...

US antivirals major Gilead Sciences (Nasdaq: GILD) yesterday released positive top-line results from the Phase III ASCENT-03 ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Good morning, and welcome to Mersana Therapeutics First Quarter 2025 ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...